Dear Colleagues,

Endorsed and supported by Chinese Biopharmaceutical Association(CBA) and SAPA-GP, we’d like to invite you to participate in Biologics Innovation and Frontier Technology (BIFT China 2020, www.biftsummit.com) to be held on December 9 and 10, 2020 in Shanghai, China, a branded Biopharma R&D and Bioprocessing Summit in China well attended by world leading biopharma and biotech companies and top CDMO, CRO and research institutes in China and Asia.

As a premier bioinnovation and bioprocessing event in China, the 4th Biologics Innovation and Frontier Technology (BIFT) China Summit 2020 will attract 600+ senior level attendees and feature higher speaker lineup, deeper insights, and real technical case studies from leading biopharma and GCT players in China. Comprehensive topics will cover development of the next generation of new therapeutic biological products in China (antibodies, cell products, gene therapy virus products), bispecific antibodies development and CMC strategies, Antibody-Drug Conjugates development, cell line and upstream process development, viral safety and clearance of biologics, downstream processing, single-use systems, continuous production, contract manufacturing, cGMP manufacturing quality control etc.

 

Snapshots of BIFT China 2020

  • Recent Trends and Development for Antibody Therapeutics in China
  • Novel Antibody Development and Immuno-Oncology
  • Clinical Trial Design, Combination Therapy for Innovative Biologics Trails
  • Innovative Platform for Bispecific Antibody Discovery and Engineering
  • Antibody-Drug Conjugates Development and Production
  • Advancement in Cell Line Development and Clone Selection Technologies
  • Quality Control, Protein Characterization, cGMP and Contract Manufacturing
  • Innovative Bio-manufacturing Technologies (including Continuous Processing, Single-use Systems and QbD/PAT)
  • Biologics Formulation, Aggregation and Stability Studies
  • Next-gen Innovative Cell & Gene Therapeutics Development (CAR-T, TCR-T, TIL, AAV…)
  • Viral and Cell therapy CMC, GMP Production and Quality Control

 

Eminent Speakers and VIPs  in BIFT China 2020

Ning Li, General Manager, Junshi Pharma

Scott Liu, President, Henlius Bio

Qinwei Zhou, COO, Innovent Bio

Zhenping Zhu, President R&D, 3S Bio

Haibin Wang, Senior Vice President, Hisun Pharma

Tongtong Xue , CEO, Kelun Biotech

Charlie Qi, Oncology head, Roche China

Biao Zhen, CSO, GenFleet Therapeutics

Robert Zhao, CEO & Chairman, Hangzhou DAC Biotech

Mary Hu, CEO, Miracogen Inc.

Yi Zhang, Director, Biotherapy Center, The First Affiliated Hospital of Zhengzhou University

James Li, CEO, JW Therapeutics

Lulu Lv, CEO, Juventas

Min Luo, CSO, Bio-gene

Feifei Qi, CTO, Immunochina

Lietao Li, CEO, BioSyngen

Hangwen Li, CEO, Stemirna Therapeutics

Ming Wang, President & CEO, Phanes Therapeutics

Xinpo Jiang, Senior Director, Legend Biotech

Bin Li, Deputy Director, Shanghai Institute of Immunology

etc…

 

Why BIFT China 2020

■500+ delegates from over 10 countries and regions

■100+ attending organizations

■40+ eminent speakers from biopharma, biotech and bioprocess companies

■70% on average attendees from primary market (biopharmas, CROs, CMOs etc)

■60% above company decision making and director level

■1 main conference and 4 focused streams

Pictures of BIFT China 2019
Jianwei Zhu
Jianwei ZhuDean and Professor, Shanghai Jiaotong University School of Pharmacy
Harry Lam
Harry LamExecutive Vice President, JW Therapeutics
Ting He
Ting HeCEO, ImmunoChina
Chunming Rao
Chunming RaoDirector, National Institute for Food and Drug Control

Partial Top Participating Biopharmas in China and Asia

Alphamab Kanda Biotech
Askesobio LG Life Sciences
Astra Zeneca Livzon Mab
Beigene Luye Pharma
Biocon India Mabspace
Boehringer Ingelheim (China) AVRDC Mabventure
Boehringer Ingelheim (China) Biopharma Newsummit Bio
Celltrion Remegen Bio
CPGP Pharma Samsung Bioepis
Destiny Bio Shanghai Acebright Pharma
Dingfu Bio Shanghai Benemae Pharmaceutical
EirGenix Shanghai Biomab
Fudan Zhangjiang Bio Shanghai Institute of Biological Products
Furen Bio Simcere
Genrix Bio Syndegen
Gmax Biopharma Tasly Pharma (Shanghai)
Haiyan Pharma Teruisi Pharma
Henlius Bio T-mab Bio
Henri Medicine Shanghai TOT Biopharma
Hisun Pharma United Biomedical
Huabo Bio Walvax Genor Bio
Hualan Bio Wuxi Apptec
Huaota Bio YZY Bio
Innovent Bio Zerun Bio
JHL Bio Zhangjiang Biotechnology

For more information, feel free to contact the organizing committee at 8621-31123968